TAP2 and cancer: In addition, reloading of the HER2369-377 peptide prominently increased the tumor-antigen specific killing by HLA-A2-HER2369-377 specific T-cells in TAP2-deficient cancer cells with minimal effect in parental controls or in TAP2-deficient cells exposed to MAGE3271-279 (Supplementary Fig. S6B-C). Together, these results indicate a prominent role of HLA-peptide complexes in tumor-antigen specific T-cell recognition and killing.